Literature DB >> 20981675

Evidence of persistent neurologic injury following thrombotic thrombocytopenic purpura.

Spero R Cataland1, Marie A Scully, James Paskavitz, Paul Maruff, Leslie Witkoff, Ming Jin, Nicholas Uva, James C Gilbert, Haifeng M Wu.   

Abstract

Despite improvements in our understanding of the pathophysiology of thrombotic thrombocytopenic purpura (TTP), little data exist regarding the long-term sequelae following a diagnosis of TTP. We present the results of a comprehensive evaluation of neurologic injury that included a magnetic resonance imaging (MRI), a neurocognitive testing, and an evaluation of health-related quality of life. Twenty-seven patients with a history of idiopathic TTP functioning normally in their activities of daily living were recruited from existing patient cohorts at both the Ohio State University (n 5 12) (Columbus) and the University College London Hospitals (n 5 15) (London, UK). Nine of 23 (39%) of the MRI studies were abnormal; 17/27 (63%) patients demonstrated neurocognitive impairment, particularly in tests of visual learning and memory. Health-related quality of life scores were also significantly lower than age- and gender-matched US norms for both the composite mental component score and physical component score. These data suggest that the prevalence of neurologic findings in TTP patients in remission is quite high and is largely undetected by routine clinical evaluations. Further longitudinal study will be required to define the risk for neurologic injury and the long-term prognosis in patients previously diagnosed with TTP.

Entities:  

Mesh:

Year:  2011        PMID: 20981675     DOI: 10.1002/ajh.21881

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  15 in total

Review 1.  TTP: long-term outcomes following recovery.

Authors:  James N George
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Severe, persistent neurotoxicity after transplant-associated thrombotic microangiopathy in a pediatric patient despite treatment with eculizumab.

Authors:  Michelle Schoettler; Christine Duncan; Leslie Lehmann
Journal:  Pediatr Transplant       Date:  2019-03-03

3.  Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura.

Authors:  Cassandra C Deford; Jessica A Reese; Lauren H Schwartz; Jedidiah J Perdue; Johanna A Kremer Hovinga; Bernhard Lämmle; Deirdra R Terrell; Sara K Vesely; James N George
Journal:  Blood       Date:  2013-07-09       Impact factor: 22.113

4.  Stroke and myocardial infarction in hereditary thrombotic thrombocytopenic purpura: similarities to sickle cell anemia.

Authors:  Azra Borogovac; James N George
Journal:  Blood Adv       Date:  2019-12-10

5.  Reduced ADAMTS13 activity during TTP remission is associated with stroke in TTP survivors.

Authors:  Harshvardhan Upreti; Jamil Kasmani; Kathryn Dane; Evan M Braunstein; Michael B Streiff; Satish Shanbhag; Alison R Moliterno; C John Sperati; Rebecca F Gottesman; Robert A Brodsky; Thomas S Kickler; Shruti Chaturvedi
Journal:  Blood       Date:  2019-08-20       Impact factor: 22.113

6.  ISTH guidelines for treatment of thrombotic thrombocytopenic purpura.

Authors:  X Long Zheng; Sara K Vesely; Spero R Cataland; Paul Coppo; Brian Geldziler; Alfonso Iorio; Masanori Matsumoto; Reem A Mustafa; Menaka Pai; Gail Rock; Lene Russell; Rawan Tarawneh; Julie Valdes; Flora Peyvandi
Journal:  J Thromb Haemost       Date:  2020-09-11       Impact factor: 5.824

7.  Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura.

Authors:  Elie Azoulay; Philippe R Bauer; Eric Mariotte; Lene Russell; Paul Knoebl; Ignacio Martin-Loeches; Frédéric Pène; Kathryn Puxty; Pedro Povoa; Andreas Barratt-Due; Jose Garnacho-Montero; Julia Wendon; Laveena Munshi; Dominique Benoit; Michael von Bergwelt-Baildon; Marco Maggiorini; Paul Coppo; Spero Cataland; Agnès Veyradier; Andry Van de Louw
Journal:  Intensive Care Med       Date:  2019-10-07       Impact factor: 17.440

8.  Long-term neuropsychological sequelae, emotional wellbeing and quality of life in patients with acquired thrombotic thrombocytopenic purpura.

Authors:  Silvia Riva; Ilaria Mancini; Alberto Maino; Barbara Ferrari; Andrea Artoni; Pasquale Agosti; Flora Peyvandi
Journal:  Haematologica       Date:  2019-09-26       Impact factor: 9.941

Review 9.  Thrombotic thrombocytopenic purpura.

Authors:  Paul Knöbl
Journal:  Memo       Date:  2018-08-17

10.  Novel therapies in thrombotic thrombocytopenic purpura.

Authors:  Camila Masias; Spero R Cataland
Journal:  Res Pract Thromb Haemost       Date:  2017-12-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.